| Efficacy and safety of iruplinalkib (WX-0593) in ALK -positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT) | |
| Yuankai Shi1; Jianhua Chen2; Helong Zhang3; Zhihong Zhang4; Yiping Zhang5; Zhehai Wang6; Shucai Zhang7; Jian Zhao8; Chunling Liu9; Xiuwen Wang10; Yanqiu Zhao11; Changlu Hu4; Lei Yang12; Xuezhi Hao1; Lin Wang1; Yunpeng Liu13; Yan Yu14; Jun Zhao15; Mengzhao Wang16; Liangming Zhang17; Sanyuan Sun18; Yanping Hu19; Kangsheng Gu20; Xiaosheng Hang21; Jinlu Shan22; Yu Zhang23; Bangxian Tan24; Weihua Yang25; Runxiang Yang26; Meimei Si27; Huaize Geng27; Hui Li27; Xiaoyan Kang27 | |
| 发表期刊 | BMC MEDICINE
 |
| ISSN | 1741-7015 |
| 卷号 | 21期号:1 |
| 英文摘要 | Iruplinalkib (WX-0593) is an anaplastic lymphoma kinase (ALK) ALK -positive crizotinib-resistant advanced non-small cell lung cancer (NSCLC) patients. |
| 语种 | 英语 |
| 文献类型 | 期刊论文 |
| 条目标识符 | http://ir.yic.ac.cn/handle/133337/34543 |
| 专题 | 中国科学院烟台海岸带研究所 |
| 作者单位 | 1.中国医学科学院北京协和医学院 2.Hunan Tumor Hospital 3.the Second Affiliated Hospital of Air Force Medical University 4.Anhui Provincial Cancer Hospital 5.Zhejiang Cancer Hospital 6.Respiratory Medical Oncology Ward II, Shandong Provincial Institute of Cancer Prevention and Treatment 7.首都医科大学 8.广州医科大学 9.The Affiliated Tumour Hospital of Xingjiang Medical University 10.山东大学 11.郑州大学 12.Gansu Province Cancer Hospital 13.中国医科大学 14.哈尔滨医科大学 15.北京大学 16.北京协和医学院 17.中国科学院烟台海岸带研究所 18.Xuzhou Central Hospital 19.Hubei Cancer Hospital 20.安徽医科大学 21.江南大学 22.Army Medical Center of PLA 23.中国科学院南京地理与湖泊研究所 24.川北医学院 25.Shanxi Provincial Cancer Hospital 26.Yunnan Cancer Hospital 27.Qilu Pharmaceutical Co., Ltd. |
| 推荐引用方式 GB/T 7714 | Yuankai Shi,Jianhua Chen,Helong Zhang,et al. Efficacy and safety of iruplinalkib (WX-0593) in ALK -positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)[J]. BMC MEDICINE,21(1). |
| APA | Yuankai Shi.,Jianhua Chen.,Helong Zhang.,Zhihong Zhang.,Yiping Zhang.,...&Xiaoyan Kang. |
| MLA | Yuankai Shi,et al."Efficacy and safety of iruplinalkib (WX-0593) in ALK -positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)".BMC MEDICINE 21.1 |
| 条目包含的文件 | 条目无相关文件。 | |||||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论